Cure My Disease

Don't miss your cure!

 Log in / Sign up

First human tests begin for experimental drug CBP-0276

NCT ID NCT07708831

Completed Knowledge-focused Sponsor: Clarent Biopharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-stage trial evaluates the safety and tolerability of an experimental drug called CBP-0276 in healthy adults aged 18 to 64. Participants receive either the drug or a placebo in single or multiple doses, and researchers monitor for side effects and how the drug moves through the body. The study also looks at how food affects drug absorption. Results will help determine whether further testing in patients is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called CBP-0276
What this could lead to
If safe, this could pave the way for future studies testing CBP-0276 in people with specific diseases.
What could go wrong
This is a very early, small study in healthy volunteers, so it cannot yet say whether the drug works for any condition. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

  • Centro de Investigación Clínica y Medicina Traslacional (CiMeT)

    Guadalajara, Jalisco, 44340, Mexico

  • Innovacion y Desarrollo en Ciencias de la Salud (IDeCSa)

    Mexico City, 14090, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.